PROSTATE-SPECIFIC ANTIGEN AFTER ANATOMIC RADICAL RETROPUBIC PROSTATECTOMY

Catalona, 1994, Five-year tumor recurrence rates after anatomic radical retropubic prostatectomy for prostate cancer, J Urol, 152, 1837, 10.1016/S0022-5347(17)32397-2

Chodak, 1994, Results of conservative management of clinically localized prostate cancer, N Engl J Med, 330, 242, 10.1056/NEJM199401273300403

Epstein, 1993, Correlation of pathologic findings with progression following radical retropubic prostatectomy, Cancer, 71, 3582, 10.1002/1097-0142(19930601)71:11<3582::AID-CNCR2820711120>3.0.CO;2-Y

Epstein, 1993, Influence of capsular penetration on progression following radical prostatectomy: A study of 196 cases with long-term follow-up, J Urol, 150, 135, 10.1016/S0022-5347(17)35415-0

Epstein, 1996, Prediction of progression following radical prostatectomy: A multivariate analysis of 721 men with long-term follow-up, Am J Surg Pathol, 20, 286, 10.1097/00000478-199603000-00004

Johansson, 1992, High 10-year survival rate in patients with early, untreated prostatic cancer, JAMA, 267, 2191, 10.1001/jama.1992.03480160049033

Jones, 1992, Prospective, conservative management of localized prostate cancer, Cancer, 70, 307, 10.1002/1097-0142(19920701)70:1+<307::AID-CNCR2820701319>3.0.CO;2-N

Moskowitz, 1987, Cancer of the prostate: Is there a need for aggressive treatment?, Urol Int, 42, 49, 10.1159/000281849

Oefelein, 1995, The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies, J Urol, 154, 2128, 10.1016/S0022-5347(01)66713-2

Oesterling, 1991, Prostate-specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate, J Urol, 145, 907, 10.1016/S0022-5347(17)38491-4

Ohori, 1995, Can radical prostatectomy alter the progression of poorly differentiated prostate cancer?, J Urol, 154, 1818, 10.1016/S0022-5347(01)66792-2

Partin, 1993, Serum PSA after anatomic radical prostatectomy: The Johns Hopkins Experience after 10 years, Urol Clin North Am, 20, 713, 10.1016/S0094-0143(21)00924-1

Partin, 1990, Prostate specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia, J Urol, 143, 747, 10.1016/S0022-5347(17)40079-6

Partin, 1994, Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases, Urology, 43, 649, 10.1016/0090-4295(94)90180-5

Schroder, 1992, The TNM classification of prostate cancer, Prostate, 4, 129, 10.1002/pros.2990210521

Trapasso, 1994, The incidence and significance of detectable levels of serum PSA after radical prostatectomy, J Urol, 152, 1821, 10.1016/S0022-5347(17)32394-7

Walsh, 1995, The natural history of localized prostate cancer: A guide to therapy, 4

Whitmore, 1991, Expectant management of localized prostatic cancer, Cancer, 67, 1091, 10.1002/1097-0142(19910215)67:4<1091::AID-CNCR2820670437>3.0.CO;2-J

Zincke, 1994, Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer, J Urol, 152, 1850, 10.1016/S0022-5347(17)32399-6